Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Ocera Therapeutics, Inc. | a13-26131_1ex99d1.htm |
UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): December 5, 2013
OCERA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
DELAWARE |
|
001-35119 |
|
63-1192270 |
|
(State or other jurisdiction |
|
(Commission File Number) |
|
(I.R.S. Employer |
|
of |
|
|
|
Identification No.) |
|
incorporation) |
|
|
|
|
|
525 University Avenue, Suite 610 |
|
|
|
Palo Alto, CA |
|
94301 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code (650) 475-0158
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 5, 2013, David S. Moore, the chief business officer of Ocera Therapeutics, Inc. (the “Company”) tendered his resignation. In addition, on December 5, 2013, the Company provided notice to Rhonda L. Stanley, the Company’s controller and principal accounting officer, of its intent to terminate her employment. Jeryl L. Hilleman, the Company’s chief financial officer and secretary, and principal financial officer, will assume the role of principal accounting officer effective immediately.
A copy of the Company’s press release regarding the foregoing is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press release of Ocera Therapeutics, Inc. dated December 11, 2013 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
December 11, 2013 |
Ocera Therapeutics, Inc. | |
|
|
|
|
|
|
By: |
/s/ Linda S. Grais, M.D. |
|
|
Name: Linda S. Grais, M.D. | |
|
|
Title: President and Chief Executive Officer | |